Home » Newsletters » BioWorld Science

BioWorld Science

May 9, 2017

View Archived Issues

Seattle Genetics and Immunomedics terminate license agreement for sacituzumab govitecan

Novo Nordisk reports key developments of first quarter 2017

Noninvasive panel of four markers can diagnose, monitor NASH

TherapeuticsMD receives complete response letter from FDA for TX-004HR as treatment of dyspareunia

Preclinical and interim phase I data for mRNA vaccine against H10N8 influenza virus

Uveitis candidate PP-001 displays ocular tolerability in vivo

Phase II results demonstrate IPV-Al vaccine is highly immunogenic in healthy infants

FDA grants fast track status to Axsome's AXS-05

Regeneron enters agreements with Inovio and SillaJen for combination studies of REGN-2810

Altimmune and PharmAthene complete merger

Durect enters Posimir development and commercialization agreement with Sandoz

Embera NeuroTherapeutics' EMB-001 well tolerated in phase Ib cocaine interaction study

FDA awards fast track status to Oncolytics Biotech's Reolysin for metastatic breast cancer

TLR8 agonism as a mechanism of action to treat chronic hepatitis B

Board recommends continuation of Fibrocell Science's phase I/II study of FCX-007

Elasmogen and Feldan announce research collaboration with Amgen

Novaliq announces successful application of first-in-class approach for treatment of dry eye disease

Exscientia and Sanofi enter agreement on bispecific small-molecule drugs for metabolic disease

Syros initiates phase I study of SY-1365 in advanced solid tumors

Polyphor discovers novel Pin1 inhibitors

Incyte describes new programmed cell death protein 1 inhibitors